Diabetes mellitus, Internal medicine, Type 2 diabetes, Endocrinology and Surgery are his primary areas of study. David R. Matthews works in the field of Diabetes mellitus, namely Type 2 Diabetes Mellitus. His research in Type 2 Diabetes Mellitus tackles topics such as Adverse effect which are related to areas like Guideline.
His work in Internal medicine addresses subjects such as Placebo, which are connected to disciplines such as Gastroenterology. His Type 2 diabetes research integrates issues from Metformin, Disease management, Family medicine and Intensive care medicine. His Disease management study combines topics from a wide range of disciplines, such as Vildagliptin, Lixisenatide and Insulin degludec.
His primary areas of study are Internal medicine, Diabetes mellitus, Endocrinology, Type 2 diabetes and Insulin. His study in Internal medicine is interdisciplinary in nature, drawing from both Placebo and Canagliflozin. He is interested in Type 2 Diabetes Mellitus, which is a field of Diabetes mellitus.
His studies in Type 2 diabetes integrate themes in fields like Gastroenterology, Adverse effect, Disease management and Family medicine. David R. Matthews combines subjects such as Type 1 diabetes and Homeostasis with his study of Insulin. David R. Matthews combines subjects such as Clinical trial, Glycemic and Smoking cessation with his study of Intensive care medicine.
David R. Matthews mostly deals with Internal medicine, Type 2 diabetes, Canagliflozin, Diabetes mellitus and Placebo. His research integrates issues of Liraglutide, Semaglutide and Empagliflozin in his study of Internal medicine. His Type 2 diabetes research incorporates elements of Metformin, Insulin, Kidney disease, Gastroenterology and Combination therapy.
His study in Diabetes mellitus is interdisciplinary in nature, drawing from both Heart failure, Intensive care medicine, Disease, Myocardial infarction and Placebo-controlled study. His studies in Placebo integrate themes in fields like Diabetic retinopathy, Clinical trial, Adverse effect, Nephropathy and Post-hoc analysis. The Type 2 Diabetes Mellitus study which covers Clinical endpoint that intersects with Randomization.
His primary areas of investigation include Internal medicine, Type 2 diabetes, Canagliflozin, Diabetes mellitus and Placebo. His Internal medicine research is mostly focused on the topic Randomized controlled trial. His studies deal with areas such as Diabetic retinopathy, Insulin and Hazard ratio as well as Type 2 diabetes.
His Canagliflozin study integrates concerns from other disciplines, such as Empagliflozin, Albuminuria, Renal function and Heart failure. His Diabetes mellitus research includes themes of Placebo-controlled study and Intensive care medicine. His Placebo study deals with Clinical trial intersecting with Adverse effect and Glycated haemoglobin.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Homeostasis model assessment : insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
D. R. Matthews;J. P. Hosker;A. S. Rudenski;B. A. Naylor.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
R C Turner;R R Holman;C A Cull;I M Stratton.
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
Irene M Stratton;Amanda I Adler;H Andrew W Neil;David R Matthews.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
R C Turner;R R Holman;I M Stratton;C A Cull.
The Lancet (1998)
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Rury R. Holman;Sanjoy K. Paul;M. Angelyn Bethel;David R. Matthews.
The New England Journal of Medicine (2008)
Canagliflozin and cardiovascular and renal events in type 2 diabetes
Bruce Neal;Vlado Perkovic;Vlado Perkovic;Kenneth W. Mahaffey;Dick de Zeeuw.
The New England Journal of Medicine (2017)
Use and Abuse of HOMA Modeling
Tara M. Wallace;Jonathan C. Levy;David R. Matthews.
Diabetes Care (2004)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Silvio E. Inzucchi;Richard M. Bergenstal;John B. Buse;Michaela Diamant.
Diabetes Care (2012)
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Silvio E Inzucchi;Richard M Bergenstal;John B Buse;Michaela Diamant.
Publication bias in clinical research
P.J Easterbrook;R Gopalan;J.A Berlin;D.R Matthews.
The Lancet (1991)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: